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Abstract
Background: Multidrug-resistant (MDR) tuberculosis (TB) presents a challenge for global TB control. Treating
individuals with MDR-TB infection to prevent progression to disease could be an effective public health strategy.
Young children are at high risk of developing TB disease following infection and are commonly infected by an adult in
their household. Identifying young children with household exposure to MDR-TB and providing them with MDR-TB
preventive therapy could reduce the risk of disease progression. To date, no trials of MDR-TB preventive therapy have
been completed and World Health Organization guidelines suggest close observation with no active treatment.
Methods: The tuberculosis child multidrug-resistant preventive therapy (TB-CHAMP) trial is a phase III cluster
randomised placebo-controlled trial to assess the efficacy of levofloxacin in young child contacts of MDR-TB cases. The
trial is taking place at three sites in South Africa where adults with MDR-TB are identified. If a child aged < 5 years lives
in their household, we assess the adult index case, screen all household members for TB disease and evaluate
any child aged < 5 years for trial eligibility. Eligible children are randomised by household to receive daily
levofloxacin (15–20 mg/kg) or matching placebo for six months. Children are closely monitored for disease
development, drug tolerability and adverse events. The primary endpoint is incident TB disease or TB death by
one year after recruitment. We will enrol 1556 children from approximately 778 households with an average of
two eligible children per household. Recruitment will run for 18–24 months with all children followed for 18
months after treatment. Qualitative and health economic evaluations are embedded in the trial.
Discussion: If the TB-CHAMP trial demonstrates that levofloxacin is effective in preventing TB disease in young
children who have been exposed to MDR-TB and that it is safe, well tolerated, acceptable and cost-effective, we
would expect that that this intervention would rapidly transfer into policy.
Trial registration: ISRCTN Registry, ISRCTN92634082. Registered on 31 March 2016.
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Background
Tuberculosis (TB) infection signifies that Mycobacterium
tuberculosis (M. tuberculosis) is present in the body with-
out causing symptoms, signs or radiological changes. TB
disease, alternatively, is associated with symptoms, signs
or radiological changes. Exposure to a person with TB dis-
ease can lead to infection with M. tuberculosis. Providing
preventive therapy to exposed contacts is a viable strategy
for reducing their risk of developing TB disease. This is
especially so for young children and people living with
HIV who, in the absence of appropriate preventive therapy,
have a higher risk of disease progression following exposure
to and infection with M. tuberculosis [1, 2].
The World Health Organization (WHO) estimated
that 558,000 individuals developed multidrug-resistant
(MDR) TB disease in globally in 2017 [3]. MDR-TB is
defined as TB disease caused by M. tuberculosis resistant
to rifampicin and isoniazid. With the rollout of rapid
molecular diagnostic tools including Xpert MTB/RIF,
the number of diagnosed adult MDR-TB cases is in-
creasing, with associated increasing numbers of child
contacts identified. Modelling suggests that two million
children are currently living with MDR-TB infection [4]
and of the children infected with M. tuberculosis who
progress to disease, 90% will do so within 12months [5].
While treatment outcomes for MDR-TB disease in chil-
dren are considerably better than in adults [6, 7] the
treatment is complex, long, poorly tolerated and associ-
ated with frequent and significant adverse events (AE), in-
cluding ototoxicity, thyroid dysfunction, nausea and
vomiting [6, 8–10]. Child-friendly formulations of
second-line TB drugs are limited and MDR-TB disease is
expensive to treat [11, 12] with prolonged hospitalisation
being common for children. Prevention of MDR-TB dis-
ease in children is therefore of paramount importance.
The United States Centers for Disease Control identified
the need for a trial of MDR-TB preventive therapy in 1992
[13]. Since then numerous international agencies have
also recommended that such a trial should be a global
health priority [14–20] but none have been completed to
date, despite the global increase in MDR-TB.
There is strong evidence for the efficacy of isoniazid to
reduce the risk of progression to TB disease in child and
adult contacts of people with drug-susceptible TB [21, 22].
Isoniazid monotherapy, given daily for six months, is
therefore recommended by the WHO in children aged
< 5 years and HIV-infected individuals, regardless of
age, following exposure to infectious drug-susceptible
TB [5, 21–24]. However, the WHO does not currently
recommend any specific drug regimen for the contacts
of people who are living with infectious MDR-TB. No
randomised controlled trials have been completed to
assess the efficacy of any regimen to prevent MDR-TB
[25], but a recent systematic review and meta-analysis of
multiple observational studies of MDR-TB preventive
therapy concluded that although the results should be
interpreted cautiously, a number of different regimens
were associated with a reduction in the risk of subsequent
TB disease and were cost-effective [26]. Our primary
hypothesis is that levofloxacin, given daily for six months,
will protect children exposed to MDR-TB from developing
TB disease. We also hypothesise that this treatment will
be well tolerated, safe and cost-effective.
Methods
Trial design
The tuberculosis child multidrug-resistant preventive
therapy (TB-CHAMP) trial is a phase III cluster rando-
mised placebo-controlled trial to assess the efficacy of levo-
floxacin to prevent TB disease in young (aged < 5 years)
child contacts of people with MDR-TB disease.
Rationale for trial design
Target population
This trial specifically targets child household contacts of
MDR-TB cases aged < 5 years for two reasons. First,
children aged < five years are at the highest risk of pro-
gressing to TB disease following infection [2]. Second,
concordance of drug susceptibility test (DST) results is
high between adults with MDR-TB and young child
household contacts [27–29]. Young child household con-
tacts are therefore most likely to benefit from MDR-TB
preventive therapy. In addition, global policy and most
national guidelines in high-burden settings recommend TB
preventive therapy only for child contacts aged < 5 years or
for children living with HIV, following exposure to a person
with drug-susceptible TB [30]. Although children aged > 5
years, living with HIV, would likely benefit from preventive
therapy, the potential for reduced concordance with the
identified source case meant that the decision was made to
restrict the trial to children aged < 5 years. Children aged
< 5 years will be enrolled, regardless of tuberculin skin test
(TST) or interferon-gamma release assay (IGRA) status.
This is a deliberate decision to ensure programmatic rele-
vance, since the WHO and most National TB Programmes
in high-burden TB settings do not require a positive test of
TB infection before initiating preventive therapy in
children who have been exposed to a person living with
infectious drug-susceptible TB [31].
Choice of intervention regimen
We considered a wide range of anti-TB drugs and drug
combinations for the intervention arm of the trial, includ-
ing first-line TB drugs, third generation fluoroquinolones,
ethionamide, para-aminosalicylic acid (PAS), cycloserine,
linezolid and clofazimine, and the novel drugs, bedaquiline
and delamanid. We discounted drugs if: (1) resistance was
likely to be present to that drug in MDR strains (the
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first-line drugs) [32, 33]; (2) the drug is likely to be poorly
tolerated (ethionamide and PAS); (3) the drug is associ-
ated with frequent or serious AEs (cycloserine, linezolid,
clofazimine); (4) the drug is only weakly effective in killing
M. tuberculosis (cycloserine, clofazimine, PAS); or (5) ap-
propriate formulations are unavailable or pharmacokinetic
parameters are not well understood (delamanid and
bedaquiline).
We therefore decided to use a third-generation fluoro-
quinolone. These drugs have good efficacy against M. tu-
berculosis in vitro and are a core component of MDR-TB
disease treatment regimens in both adults and children.
Historically, clinicians had been hesitant to use fluoroqui-
nolones in children following early animal research
demonstrating cartilage damage in juvenile beagles [34].
However, a significant body of evidence has now demon-
strated that drugs of this class are safe in children, even
for long-term use [9, 35–38]. Although moxifloxacin has
good efficacy against metabolically active mycobacteria,
levofloxacin may have better activity against metabolically
inactive mycobacteria [39]. A mouse model which evalu-
ated a number of novel TB infection treatment regimens
in a latent infection model found that levofloxacin, moxi-
floxacin and isoniazid had similar efficacy against drug-
susceptible strains of M. tuberculosis. Moxifloxacin is
poorly tolerated in its current formulation due to its bitter
taste and there are challenges in taste masking the active
ingredient [40]. In addition, the large milligram size of the
tablet (400mg) makes dosing challenging in children.
Levofloxacin, in contrast, has a low tablet milligram dose,
is licensed for children, has been widely used to treat
paediatric MDR-TB disease and other bacterial infections,
has known pharmacokinetic parameters when used at
once-daily dosing [41], does not interact with antiretro-
viral therapy drugs and appears to have low toxicity at
currently used dosages [42].
Some limited rationale exists for the additional use of
isoniazid in a preventive therapy regimen, as it would be
efficacious in preventing disease if the child had been
exposed to a person with drug-susceptible TB in addition
to the identified MDR-TB case. As young children are
likely to be highly concordant with the identified source
case, we anticipate few children acquiring drug-susceptible
organisms. Isoniazid may also provide some efficacy
against MDR strains with inhA promoter region mutations
(typically conferring low-level resistance) [43]. Globally,
however, isoniazid resistance is more commonly caused by
katG gene mutations [44], in which isoniazid is less likely
to be effective. For these reasons we elected not to include
isoniazid in the intervention regimen. Paediatric pharma-
cokinetic and safety data for delamanid are becoming
increasingly available and the WHO now recommends
delamanid for the treatment of MDR-TB disease in chil-
dren aged as young as six years, but not yet to the youngest
children, where treatment of infection is most needed [45].
We plan to adapt the trial design to include delamanid to
treat child contacts of fluoroquinolone-resistant MDR-TB,
in an observational cohort, once pharmacokinetic data and
formulations become available for the youngest children,
dependent on additional funding.
In designing our intervention, we also considered that a
simple regimen with one drug would likely be safer and
would facilitate easier adherence for children. Although
concerns have been raised that the use of a single drug
could lead to the acquisition of secondary resistance in
individuals who develop TB disease, this has not been
shown to occur with the use of isoniazid as a single agent
for TB preventive therapy in adult and child contacts of
drug-susceptible TB [21, 46]. We therefore decided to use
levofloxacin alone.
Choice of control regimen
As outlined above, isoniazid may be active against M. tu-
berculosis with inhA promoter region mutations, as well as
susceptible strains from exposures other than the identified
index case. For these reasons, the PHOENIx randomised
controlled trial (A5300/IMPAACT2003), evaluating MDR-
TB infection treatment with delamanid, chose isoniazid for
their control arm. However, as also stated above, we antici-
pate high concordance between index case and child con-
tact (with few children infected with drug-susceptible
strains), as well as globally limited utility of isoniazid to
treat MDR strains (due to the preponderance of katG gene
mutations worldwide). In addition, the inclusion of isonia-
zid would increase the (albeit low) risk of harm that could
arise through the use of a potentially hepatotoxic drug.
Given the lack of evidence for the efficacy for isoniazid to
treat MDR-TB infection and the lack of guidance on this
topic, the protocol team, after broad scientific and ethical
consideration, determined that it would be most appropri-
ate to use no active drug in the control arm. This repre-
sents current WHO guidance [31].
Blinding
We considered using an open-label design. However, the
primary trial endpoint, incident TB, although standardised
to as great a degree as possible, remains, to some extent,
subjective. Many children who develop incident TB during
the trial will be diagnosed clinically (i.e. not bacteriologically
confirmed). The study team felt that with an open-label de-
sign there may be bias in the ascertainment of the endpoint.
Children known not to be receiving any medication may be
followed more closely and investigated more intensively
than children known to be on treatment. In addition, there
would be potential for bias in the ascertainment and report-
ing of AEs, with families/caregivers potentially more likely
to report AEs if they knew their child was taking an active
treatment. We therefore decided blinding and use of
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placebo would support unbiased assessment of endpoints
and toxicity.
Clustering
As we planned to identify and treat children in their
households, we felt that all children in the same household
should be randomised to the same trial arm. Randomisa-
tion by household allows for ease of drug administration
and protection from bias through accidental or deliberate
switching of tablets (levofloxacin/placebo) between child
household contacts. The statistical implications of the
clustering are accounted for in the sample size estimation
and analysis plan.
Context
South Africa had an estimated TB incidence of 834 cases
per 100,000 in 2015 with 3.5% of new cases and 7.1% of
previously treated TB cases having either MDR-TB or
rifampicin-resistant-TB [3]. The national HIV antenatal
prevalence was 29.7% in 2013 [47]; in 2015, of all TB
patients with known HIV status, 57% were estimated to
be HIV-infected [3]. The trial is being conducted at
three sites in South Africa, all of which have extensive
research experience in TB trials: (1) Desmond Tutu TB
Centre, Stellenbosch University, Cape Town; (2) Perinatal
HIV Research Unit, Wits Health Consortium, Klerksdorp;
and (3) Wits Reproductive Health and HIV Institute, Wits
RHI Shandukani Research Centre, Johannesburg. Trial
management, statistical design and analysis, and clinical
event management is provided by the Medical Research
Council Clinical Trials Unit (MRC CTU) at University
College London. The trial began recruitment in September
2017 and recruitment is planned over 18–24months. All
children receive 24 weeks of therapy and are followed for
72 weeks after treatment.
Trial endpoints
The primary endpoint is incident TB disease (bacterio-
logically confirmed or clinically diagnosed) or TB death
by 48 weeks following randomisation. Incident TB and
cause of death are adjudicated by an independent End-
point Review Committee blinded to treatment allocation,
based on available clinical, radiological, microbiological
and molecular data using standard case definitions (see
Table 1). Secondary endpoints are: (1) all-cause mortality;
(b) AEs ≥ grade 3 (possibly or likely associated with
drug treatment) during 24 weeks of treatment; (3) per-
centage of levofloxacin or levofloxacin-placebo doses
ingested and retained over 24 weeks of treatment; (4) TB
disease over 96 weeks; and (5) incidence of levofloxacin-
resistant TB disease.
Trial conduct
Index case identification
Adult MDR-TB index cases are identified via routine
National TB Programme TB clinics/hospitals or via other
(e.g. laboratory-based) surveillance methods and assessed
for eligibility as index cases (Table 2). Adults are
approached at their local clinic/hospital or at home to
provide consent for collection of their TB episode data
and a sputum sample, and for permission to conduct a
home visit to enumerate all household members and
eligible child contacts (Fig. 1).
Household assessment
Following the evaluation of an adult MDR-TB index
case, home visits are undertaken and the household con-
tacts enumerated. Comprehensive infection control proce-
dures are followed to protect staff. Screening is conducted
in all household contacts to identify those with prevalent
TB disease, to rule out additional individuals who may
have drug-susceptible-TB and to identify child household
contacts who do not have prevalent TB disease and who
are eligible for enrolment. Household characteristics and
children’s TB exposure are captured using a standard
approach [48]. All household members aged ≥ 5 years with
suggestive symptoms are referred for TB investigation and
TB/HIV care as appropriate.
Definition of household
Households are defined using a standard inclusive defin-
ition [49]. A household contact is defined as a person who
currently lives or lived in the same dwelling unit or plot of
land and shares or shared the same housekeeping arrange-
ments as the adult MDR-TB index case, and where there
is reported exposure within six months before the index
case starting MDR-TB treatment.
Screening children for eligibility
Written informed consent from caregivers is obtained to
screen for study entry and eligibility (Table 2). Children
aged < 5 years who are identified as having been living in
the same household as an enrolled adult MDR-TB index
case at any point during the preceding six months are
eligible, if the exposure has lasted > 2 weeks. Anthropo-
metric measurements are completed, TB symptoms and
signs captured, and chest radiographs (CXR), HIV testing
and IGRA (QuantiFERON-TB Gold Plus; Qiagen) done.
Any children with suggestive symptoms or signs of intra-
thoracic or extrathoracic TB disease, or with concerning
CXR features, are investigated for TB disease (including
sampling for bacteriological testing) and are referred for
TB care if TB is diagnosed. If any adult is identified with
isoniazid- or rifampicin-susceptible TB in the household,
then all children in the household become ineligible. Any
child found to have been in contact with an index case
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who has isoniazid- or rifampicin-susceptible TB will be
referred to the local clinic to access preventive therapy, as
per WHO guidelines. Prevalent TB in child contacts is de-
fined using standard international case definitions for
paediatric TB in contact investigation studies (Table 1)
which have been harmonised between three international
MDR-TB preventive therapy protocols (TB-CHAMP,
V-QUIN and the ACTG/IMPAACT PHOENIx trials).
CXR findings suggestive of intrathoracic (pulmonary) TB
are defined in Table 3.
Child enrolment
Carers/legal guardians of child household contacts are
approached; consent is obtained for screening and, if
eligibility is confirmed, subsequent enrolment.
Randomisation
All eligible contacts in a household consenting to partici-
pate are allocated to the same study arm, but participation
of all eligible child household contacts is not required for
the household to participate. Enrolment of children and
Table 1 Clinical and radiological/laboratory criteria required to make a diagnosis of confirmed, probable or possible TB in child TB
contacts aged < 5 years of age. Developed in collaboration with the trial teams from V-QUIN and PHOENIx
Clinical (A) Radiological/laboratory (B)
• Cough or cervical neck mass (≥2 × 2 cm) for > 2 weeks despite a
course of antibiotics
• Fever or lethargy for > 1 week despite a course of antibiotics
• Documented failure to thrive, i.e. flattening of weight curve crossing
centiles, documented weight loss, e.g. > 5%, moderate or severe
malnutrition (Weight-for-height Z score < − 2) in relation to previous measures
• Classic gibbus suggestive of spinal TB
• Depressed level of consciousness, new onset seizures or focal
neurological signs suggestive of TB meningitis
• AFBs or caseating granulomas on microscopy (not confirmed
by culture or Xpert to be TB)
• CXR suggestive of TB (concurrence between two blinded CXR
reviewers, with conflicts resolved by third reviewer) despite a
course of antibiotics
• CSF suggestive of TB (white cell count 10-500 cells per µl with a
lymphocyte predominance, protein > 1 g/dL, glucose < 2.2mmol/L)
• Pleural aspirate or ascitic tap with WBC counts, protein, and
glucose levels suggestive of TB, consider ADA
• CT brain suggestive of CNS TB
• Confirmed TB: positive M. tuberculosis + at least one of either A or B
• Positive M. tuberculosis: (adapted from Graham et al. [57]): at least one positive culture (with confirmed M. tuberculosis speciation) or one positive WHO-endorsed
NAAT (e.g. XpertMTB/RIF assay) from respiratory samples (expectorated/induced sputum or gastric aspirate) or other samples such as fine needle aspiration biopsy
or other fluid or tissue samples
• Probable TB: at least one of A and at least one of B
• Possible TB: at least one of A or B (but not both) and a decision to treat
• Not TB: the absence of clinical, radiological or laboratory evidence that meets any of the above criteria
• TB infection: immunological evidence of infection with M. tuberculosis (TST/IGRA) plus classification as ‘Not TB’.
• Indeterminate/unclassifiable TB status: documented results of the diagnostic evaluation (suspicious symptoms, chest radiograph, laboratory tests) are insufficient
for the Endpoint Review Panel to reach determination
• Death: mortality will be classified as death from any cause. TB deaths will be verified using available data (including death certificate, post mortem, hospital and other clinical
information or other as available). The Endpoint Review Committee will review and determine the cause of death, if there are any deaths, in all children participating in the trial.
Death occurring during a TB episode will be classified as TB death, unless there is clear evidence that the death is unrelated (e.g. motor vehicle accident)
TB tuberculosis, AFBs acid-fast bacilli, CXR chest radiograph, ADA adenosine deaminase, CNS central nervous system, CSF cerebrospinal fluid, CT computed
tomography, IGRA interferon-gamma release assay, TST tuberculin skin test, WBC white blood count, WHO World Health Organization, NAAT nucleic acid
amplification test
Table 2 Inclusions and exclusion criteria for adult index cases and child trial participants
Adult index case inclusion criteria Child participant inclusion criteria Child participant exclusion criteria
1. Age ≥ 18 years
2. Bacteriologically confirmed pulmonary TB diagnosed
from a sputum sample within the preceding 6months
3. Genotypic and/or phenotypic resistance to isoniazid
and rifampicina
4. Written informed consent to provide routine TB
episode data
5. At least 1 child household contact aged < 5 years
reported to have been residing in the same household
as the adult index case in the previous 6 months
1. Child aged < 5 years who is a household
contact of an enrolled adult MDR-TB index case
diagnosed during the previous 6 monthsb
2. Primary residence in the household of the adult
MDR-TB index case
3. Consent from the parent or legal guardian for
the child for HIV testingc
4. Consent obtained from the parent or legal
guardian for the child to be enrolled in the study
1. TB disease at enrolment
2. Currently on isoniazid or a
fluoroquinoloned for ≥ 14 days
3. Treated for TB in the previous
12 months
4. Known concurrent exposure to an
isoniazid-susceptible (including
rifampicin-monoresistant) index casee
5. Children with myasthenia gravis or
Guillain–Barré syndrome
aIf only tested by Xpert MTB/RIF or other approved molecular tests, the index case can be included if rifampicin-resistant, without other confirmed DST. Rates of
rifampicin-resistant, isoniazid-susceptible TB are very low in this context [58]. Samples found to be rifampicin-resistant will subsequently be confirmed by other
molecular testing and/or by phenotypic DST
bChildren aged < 5 years who are identified as having been living in the same household as an enrolled adult MDR-TB index case at any point during the
preceding 6 months are eligible, if the exposure has lasted > 2 weeks
cHIV-infected and uninfected children will be included
dLevofloxacin, moxifloxacin, ofloxacin or ciprofloxacin
eAny child found to have been in contact with an index case who has isoniazid- or rifampicin-susceptible TB will be referred to the local clinic to access
preventive therapy, as per WHO guidelines
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randomisation of households into the study is via a centra-
lised web-based system to maintain allocation concealment.
Randomisation is stratified by site and households are
randomised 1:1 to either levofloxacin or placebo. The ran-
domisation lists are prepared by an individual who is not
involved in the day-to-day running of the trial.
Interventions
Medications are dosed by pragmatic weight-bands (Table 4).
Children randomised to the intervention arm receive levo-
floxacin at a target dose of 15–20mg/kg per day once daily
for 24 weeks. Although this is the recommended target
dose [50], we acknowledge that higher dosages may be
needed to achieve the serum concentrations seen in adults
when dosed with 750mg once daily [51]. In addition, as
can be seen in Table 4, the use of weight-bands leads to
some over-dosing and some under-dosing for children at
the boundaries of each weight-band. Children randomised
to the control arm receive placebo formulated to look and
taste identical to the 250mg (or 100mg) levofloxacin
dispersible tablet. Drug (and placebo) is being supplied
initially as 250mg tablets. During the course of the trial, a
100mg dispersible tablet (and placebo) is expected to
become available for use in the lower weight-bands.
Follow-up
Children are seen at 4, 8, 12, 16, 24, 36, 48, 72 and 96
weeks for study visits and at any time that caregivers feel
Fig. 1 The series of activities conducted by the study team to identify eligible child contacts of multidrug-resistant tuberculosis index cases
Table 3 Chest radiograph features characteristic (‘typical or highly suggestive chest radiograph findings’ of TB in children aged < 5
years, by disease severity status)
Non-severe disease Severe disease
• Uncomplicated LN disease - hilar or mediastinal nodes, nodes with
unilateral airway narrowing, nodes with single lobe bronchopneumonia,
nodes with segmental opacification (< 1 lobe)
• Isolated Ghon focus
• Simple pleural effusion
• Complicated LN disease (airway compression with hyperinflation or
collapse or bilateral airway compression)
• Expansile pneumonia (involving ≥ 1 lobe)
• Ghon focus with cavitation
• Miliary TB
• Complicated pleural effusion (alveolar disease with effusion,
pneumothorax, loculated pyopneumothorax with air-fluid level),
loculated pleural effusion
• Adult-type cavitary disease
• Bronchopneumonic consolidation with or without cavities or
visible lymph nodes
• Suspected pericardial effusion (cardiac enlargement)
LN lymph node, TB tuberculosis
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that the child may have developed TB disease or they, or
the study team, have other concerns.
Data collection
The data collected, investigations undertaken and time
points at which these are carried out, from the index
case, household and child, are indicated in Fig. 2. The
TB treatment register at the treating clinic and National
Health Laboratory Service database are reviewed by the
study team to collect data on the index case. A sputum
sample is also collected from the index case for culture,
DST and genotyping. At follow-up study visits of the
child contacts, anthropometric measurements are recorded
and caregivers are asked questions regarding the child.
Stool is collected at selected sites for non-mycobacterial
microbiology and microbiome analysis. Any child with
symptoms or signs suggestive of TB disease, a CXR with
features consistent with TB disease, or a CXR with persist-
ent abnormalities despite a course of antibiotics, will be
evaluated for TB disease by a clinician and have two
Table 4 Weight-bands for levofloxacin (100 mg and 250 mg tablets) and resulting drug exposures
Weight-bands
(kg)
Tablets of
levofloxacin 100 (n)
Tablets of
levofloxacin 250 (n)
Range of resulting dosages (mg/kg)
Levofloxacin 100 Levofloxacin 250
Min Max Min Max
3 4.9 0.5 0.25 10 17 13 21
5 6.9 1 0.5 14 20 18 25
7 9.9 1.5 0.75 15 21 19 27
10 11.9 2 1 17 20 21 25
12 15.9 2.5 1 16 21 16 21
16 19.9 3 1.5 15 19 19 23
20 24.9 1.5 15 19
25 29.9 2 17 20
Target dosage for levofloxacin is in the range of 15–20 mg/kg
Children in the placebo arm will receive the same number of tablets based on their weight-band
Fig. 2 Schedule of evaluations. SCR screening, BL baseline – at randomisation, U/S unscheduled, TB tuberculosis, ALT alanine aminotransferase, BR
bilirubin, DST drug susceptibility test, FBC full blood count, IGRA interferon-gamma release assay, WHO World Health Organization. *If intercurrent
exposure to an isoniazid- or rifampicin-susceptible TB case, preventive therapy will be offered. **At selected sites only. #Based on clinical
indication only – TB symptoms at baseline, or at follow-up: new or persistent symptoms, or CXR changes at any time including endpoint
evaluation. HIV testing at 48 weeks will be repeated in HIV-negative participants. If HIV status is already known to be positive at screening, the
CD4 count and HIV viral load should be completed at baseline in HIV-infected children. HIV viral load is standard of care in HIV-infected children
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respiratory samples (expectorated/induced sputum or gas-
tric aspirate) collected for smear microscopy, GeneXpert
MTB/RIF and culture. If the culture is positive, the sample
undergoes DST and genotyping.
Adverse events
Safety assessments are conducted at each visit during the
24weeks on treatment and include evaluation of symptoms,
signs and laboratory investigations. At every study visit (and
at unscheduled visits) a symptom checklist prompts for
symptoms relating to possible drug toxicities. All symptom-
atic patients are evaluated by the study doctor and discussed
with the site Principal Investigator. Safety laboratory investi-
gations are performed at baseline and at 8, 16 and 24weeks
and are also performed at unscheduled visits if clinically in-
dicated. AEs (clinical and laboratory) are graded using the
2017 Division of AIDS toxicity grading scale [52]. All AEs
are recorded in the child’s notes and reported to the MRC
CTU and ethics committees as required within agreed time-
scales. There are no known drug–drug interactions between
levofloxacin and antiretroviral drugs used to treat children
living with HIV [42] and a recent evaluation of long-term
levofloxacin use in children with MDR-TB found no evi-
dence of cardiotoxicity or QTc prolongation [53].
Statistical considerations
For sample size determination, we have assumed a
two-sided superiority test (alpha of 0.05), assuming that
TB incidence in the control arm is 7% [2]. We have
powered the trial to detect a 50% reduction of the TB in-
cidence in the levofloxacin arm. We have conservatively
assumed 10% loss to follow-up [21, 35, 54], two children
per household [54] and an intra-class correlation within
households (a measure of how similar the households
are to each other) of 0.1. Other intra-class correlation
values and the impact on sample size are shown in
Table 5. Considering these assumptions, we will need to
enrol 1556 children (778 per arm) to achieve 80% power
to detect differences between the two arms (Fig. 3).
There will be one formal interim analysis using Haybittle–
Peto-type boundaries [55, 56], which will occur after
accrual of at least half the targeted number of households
or when half the target number of household contacts
(whichever is sooner) have been recruited and when these
recruited child participants have been followed for at least
six months. Primary analysis is intention to treat.
Ethical considerations
Consent
Written informed consent is obtained from the adult
MDR-TB index case to approach the household and the
parent/legal guardian of the eligible child for their screen-
ing and possible subsequent enrolment into the trial. The
consent process is conducted in the home language of the
person from whom consent is requested and that individ-
ual is given a written information sheet, also in their home
language, explaining the study. Consent is obtained before
any trial-related procedures are performed.
Registration and ethical approval
The trial has been registered, and details can be viewed
at: http://www.isrctn.com/ISRCTN92634082. The trial has
been approved by the Stellenbosch University Human
Research Ethics Committee (M16/02/009), the University
of the Witwatersrand Ethics Committee (160409) and the
Medicines Control Council, South Africa.
Oversight
The trial is run primarily by the Trial Management
Group and is overseen by the Trial Steering Committee.
An Independent Data Monitoring Committee sees confi-
dential, unblinded data for the trial and advises the Trial
Steering Committee on whether the trial needs to be
prematurely closed. An Endpoint Review Committee,
blinded to treatment arm, evaluates clinical trial end-
points and causes of death.
Sub-studies
Social science
The Social Science team will describe: (1) the percep-
tions that patients, families and health workers have
about TB care and prevention, as well as the
TB-CHAMP trial; (2) how the study intervention is im-
plemented in the context of local health systems; and (3)
the families’ experiences of the trial. This involves key in-
formant interviews with health service personnel,
mixed-methods research around implementation and a
nested qualitative cohort.
Health economic research
Costing and cost-effectiveness of the trial interventions
for both families and health systems at the three
Table 5 Total number of households (children)a required for
80% and 90% power for varying control arm event rates and
intra-cluster correlation coefficients
Power Contacts who develop
TB disease by 48 weeks
(control arm) (%)
Intra-cluster correlation coefficients
0.05 0.1 0.15
80% 5 1056 (2122) 1108 (2216) 1158 (2316)
7 742 (1484) 778 (1556) 814 (1628)
10 508 (1016) 532 (1064) 556 (1112)
90% 5 1414 (2828) 1480 (2960) 1548 (3096)
7 994 (1988) 1040 (2080) 1088 (2174)
10 678 (1356) 710 (1420) 742 (1484)
aAssumes 2 contacts per household, 10% loss to follow-up, two-sided 5%
significance level test and a 50% risk reduction in the intervention arm
The number in italics indicates the chosen trial sample size
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collaborating sites will be evaluated. This involves col-
lecting data on costs associated with the interventions as
well as costs associated with children developing MDR-TB
disease. The primary outcome is the incremental
cost-effectiveness ratio of levofloxacin against placebo.
Drug studies
Palatability and acceptability of the new child-friendly
dispersible 100 mg levofloxacin formulation has been
evaluated in 24 children before trial start-up as part of a
lead-in pharmacokinetic sub-study. Bioavailability is also
being evaluated in healthy adult volunteers. Ongoing
evaluation of the 250mg formulation (and 100 mg for-
mulation when it becomes available) will take place
throughout the trial using questionnaires and qualitative
research.
Other sub-studies
The trial provides a unique platform to conduct a number
of basic science studies. Given that children in the placebo
arm are monitored closely without treatment (a situation
that would not be possible following exposure to drug-
susceptible TB, given the proven efficacy of isoniazid pre-
ventive therapy), this trial permits evaluation of correlates
of risk in MDR-TB-exposed children, using RNA transcrip-
tomic approaches. Blood samples are taken at the time of
routine, trial-related blood draws and stored for subsequent
analysis. Baseline and serial stool samples are taken from
children at selected sites to evaluate the impact of levofloxa-
cin on the microbiome of children and its effect on the de-
velopment of levofloxacin resistance in non-mycobacterial
bacteria. The trial provides an opportunity to use whole
genome sequencing to study the molecular epidemiology of
M. tuberculosis, the impact of drug resistance on transmis-
sion and to evaluate concordance between index cases and
household contacts.
Discussion
Should TB-CHAMP determine that levofloxacin is effect-
ive in preventing the development of TB disease in young
children who have been exposed to MDR-TB, and that it is
safe and well tolerated, we would expect that this interven-
tion would rapidly translate into policy. We will continue
to inform the WHO and other policy groups about the
trial status and findings. Although the study is being con-
ducted in only one country, the diverse nature of the trial
sites, with varied host genetics, mycobacterial strain types
and varying prevalence of drug resistance, epidemiological
characteristics, health systems and cultural practices, would
mean that the results are likely to be generalisable to
children more broadly.
Trial status
Recruitment to the trial started in September 2017. Recruit-
ment will continue until the target number of children has
been recruited. This is anticipated to take 18–24months.
The current protocol is Version 1.0 (see Additional file 1).
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (PDF 129 kb)
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